DexCom, Inc.
DXCM
Positions held
Your positionsDXCM isn't in your positions.
Add it to see shares, cost, and P&L here.
Bull / bear case
Site-generated summary from fundamentals, news, and score — not investment advice. As of 2026-10-07.
- DexCom is well-positioned in the growing continuous glucose monitoring market, which is expected to expand as diabetes prevalence increases globally.
- Revenue increased by 10% compared to the prior quarter, reaching $1.3 billion.
- Gross margin improved to 63.4%, up from 63% in the previous quarter.
- Despite strong growth, DexCom's high trailing P/E ratio of 33.09 may indicate overvaluation compared to industry peers.
- The company's score is currently neutral at 9.00, reflecting mixed market signals.
- Operating margin decreased to 24.3%, despite a previous expansion, indicating potential operational challenges.
Fundamentals
| Market cap | $31.85B | Enterprise value | $31.30B | Trailing P/E | 33.50 | Forward P/E | 26.99 |
| PEG | 2.10 | Price / book | 12.15 | Beta | 1.48 | Dividend yield | 0.00% |
| Revenue growth | 13.1% | Earnings growth | 43.6% | Gross margin | 62.5% | Operating margin | 24.3% |
| Profit margin | 20.1% | ROE | 38.5% | ROA | 10.3% | Debt / equity | 0.53 |
| Current ratio | 1.73 | Free cash flow | $1.02B | Analyst recommendation | strong_buy | Mean target | $96.23 |
| 52w high | $92.59 | 52w low | $54.11 |
Quarterly
| 2026-Q2 | 2026-Q1 | 2025-Q4 | 2025-Q3 | 2025-Q2 | |
|---|---|---|---|---|---|
| Revenue | $1.3B | $1.2B | $1.3B | $1.2B | $1.2B |
| Op margin | 24.3% | 21.4% | 25.6% | 20.1% | 18.4% |
| Net income | $249M | $200M | $267M | $284M | $180M |
| Gross margin | 63.4% | 62.9% | 62.9% | 60.5% | 59.5% |
| Gross profit | $830M | $750M | $793M | $731M | $689M |
| Operating income | $318M | $255M | $323M | $243M | $213M |
- Revenue +10% vs prior quarter ($1.3B vs $1.2B).
- Gross margin 63.4% (was 63% prior quarter).
- Operating margin expanded to 24.3%.
Yearly (6y)
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | $4.7B | $4.0B | $3.6B | $2.9B | — |
| Op margin | 19.6% | 14.9% | 16.5% | 13.4% | — |
| Net income | $836M | $576M | $542M | $341M | — |
| Gross margin | 60.1% | 60.5% | 63.2% | 64.7% | — |
| Gross profit | $2.8B | $2.4B | $2.3B | $1.9B | — |
| Operating income | $912M | $600M | $598M | $391M | — |
No flags
• No distress or material-risk keywords in recent headlines (keyword scan only — not a guarantee).
News
2026-10-08 · Citi reiterates these 2 medtech stocks as its top picks in the sector
2026-10-07 · Evercore ISI Adjusts Price Target on DexCom to $110 From $90
2026-10-07 · Flutter upgraded, AppFolio downgraded: Wall Street's top analyst calls
2026-10-06 · Dexcom U Enters Season 5 With a Record Roster and Evidence That Diabetes Stigma Among Young Athletes Is Fading
2026-10-02 · Why Medtronic’s $4 Billion MiniMed Exchange Offer Is Losing Its Allure
2026-10-02 · DXCM Report Highlights CGM Growth Opportunity in Type 2 Diabetes Care
2026-10-01 · RBC Raises Price Target on DexCom to $105 From $90, Keeps Outperform Rating
2026-10-01 · Tandem Diabetes Care (TNDM) Is Up 7.2% After International Launch Of Mobi Insulin Pump System
2026-09-29 · Beta Bionics Stock Down Despite iLet-Eversense 365 Integration Deal
2026-09-28 · This Stock Could Be the Big Winner Out of Oura’s IPO
2026-09-28 · Tandem Diabetes Expands Insulin Delivery System to 12 New Countries
Price (daily)
Full chart · RSI · MACD · patterns